LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

101.2 0.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

101.2

Максимум

102.94

Ключови измерители
By Trading Economics
Приходи	-6.3M -53M
Продажби	2.8M 51M
EPS	-0.82
Марж на печалбата	-103.131
Служители	283
EBITDA	-7.6M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+22.32% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-835M 6.7B
Предишно отваряне	100.43
Предишно затваряне	101.2

Настроения в новините

By Acuity

43%

57%

130 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.11.2025 г., 10:30 ч. UTC

Печалби

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22.11.2025 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22.11.2025 г., 09:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 22:42 ч. UTC

Пазарно говорене

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 21:47 ч. UTC

Пазарно говорене

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21.11.2025 г., 21:43 ч. UTC

Пазарно говорене

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21.11.2025 г., 20:18 ч. UTC

Пазарно говорене

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21.11.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21.11.2025 г., 19:48 ч. UTC

Пазарно говорене

Precious Metals Fall for the Week -- Market Talk

21.11.2025 г., 19:44 ч. UTC

Печалби

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21.11.2025 г., 19:37 ч. UTC

Пазарно говорене

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21.11.2025 г., 19:20 ч. UTC

Пазарно говорене

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21.11.2025 г., 18:37 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21.11.2025 г., 18:34 ч. UTC

Пазарно говорене

Печалби

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21.11.2025 г., 18:28 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 18:03 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Intuit Seen on Path to Increase Growth -- Market Talk

21.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 17:05 ч. UTC

Пазарно говорене

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21.11.2025 г., 16:56 ч. UTC

Пазарно говорене

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21.11.2025 г., 16:47 ч. UTC

Пазарно говорене

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21.11.2025 г., 16:35 ч. UTC

Придобивния, сливания и поглъщания

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21.11.2025 г., 16:09 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 15:59 ч. UTC

Пазарно говорене

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

22.32% нагоре

12-месечна прогноза

Среден 124.45 USD 22.32%

Висок 142 USD

Нисък 110 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

130 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.